公开(公告)号：EP3201227A1

公开(公告)日：2017-08-09

申请号：EP15846994.0

申请日：2015-09-29

申请人： Duke University ,  MacroGenics, Inc. ,  The University of North Carolina at Chapel Hill

发明人： HAYNES, Barton F. ,  FERRARI, Guido ,  KOENIG, Scott ,  JOHNSON, Leslie S. ,  LAM, Chia-Ying Kao ,  SUNG, Julia A. ,  MARGOLIS, David M. ,  LIU, Liqin ,  NORDSTROM, Jeffrey, Lee

IPC分类号： C07K16/10

CPC分类号： C07K16/1063 ,  A61K39/39541 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2812 ,  C07K16/283 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/626 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76

摘要： The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.

摘要翻译： 本发明涉及包含靶向效应细胞的HIV-1包膜靶向臂和臂的双特异性分子，包含这些双特异性分子的组合物和使用方法。 在某些方面，本发明的双特异性分子可结合两种不同细胞上的两种不同靶标或表位，其中第一表位在与第二表位不同的细胞类型上表达，使得双特异性分子可将两种细胞结合在一起 。 在某些方面，本发明的双特异性分子可结合两种不同的细胞，其中双特异性分子包含具有A32,7B2，CH27，CH28或CH44的结合特异性的臂。

公开(公告)号：EP4389226A2

公开(公告)日：2024-06-26

申请号：EP24171071.4

申请日：2018-02-22

申请人： MacroGenics, Inc.

发明人： LIU, Liqin ,  LAM, Chia-ying, Kao ,  DIEDRICH, Gundo ,  JOHNSON, Leslie, S. ,  MOORE, Paul, A. ,  BONVINI, Ezio

IPC分类号： A61P35/00

CPC分类号： A61P35/00 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/32 ,  A61K2039/50720130101 ,  C07K2317/2420130101 ,  C07K2317/3120130101 ,  C07K2317/3320130101 ,  C07K2317/3520130101 ,  C07K2317/56520130101 ,  C07K2317/7520130101 ,  C07K2317/7620130101 ,  C07K2317/9220130101 ,  C07K2317/9420130101 ,  G11C13/0026 ,  G11C13/004 ,  G11C15/046 ,  G11C2013/004520130101

摘要： The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD 137 and one or more epitope-binding sites specific for an epitope of a tumor antigen ("TA") (e.g., a "CD137 × TA Binding Molecule"). In one embodiment, such CD137 × TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137 × TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA. The CD137 × TA Binding Molecules of the invention are capable of simultaneous binding to CD137, and a TA. The invention is directed to pharmaceutical compositions that contain any such CD137 × TA Binding Molecules. The invention is additionally directed to methods for the use of such molecules in the treatment of cancer and other diseases and conditions. The invention also provides novel CD137-binding molecules, and HER2/neu-binding molecules, as well as derivatives thereof and uses thereof.

公开(公告)号：EP3152235A1

公开(公告)日：2017-04-12

申请号：EP15799237.1

申请日：2015-05-29

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie, S. ,  HUANG, Ling ,  CHICHILI, Gurunadh, Reddy ,  SHAH, Kalpana ,  LAM, Chia-Ying, Kao ,  BURKE, Stephen, James ,  LIU, Liqin ,  MOORE, Paul, A. ,  BONVINI, Ezio ,  BARAT, Bhaswati

IPC分类号： C07K16/18

CPC分类号： C07K16/28 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2815 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2878 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/00

摘要： The present invention relates to Tri-Specific Binding Molecules, which are multichain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

摘要翻译： 本发明涉及三特异性结合分子，其是具有三个结合域的多链多肽分子，因此能够介导与三个表位的协调结合。 三特异性结合分子的特征在于具有结合域，其允许其免疫特异性结合：（1）第一癌抗原的表位，（2）第二癌抗原的表位，和（3） 在免疫系统效应细胞的表面上表达的分子，因此能够将免疫系统效应细胞定位于表达癌抗原的细胞，从而有助于杀死这种癌细胞。

公开(公告)号：EP3954703A3

公开(公告)日：2022-05-18

申请号：EP21185550.7

申请日：2015-05-29

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie S. ,  HUANG, Ling ,  CHICHILI, Gurunadh Reddy ,  SHAH, Kalpana ,  LAM, Chia-Ying, Kao ,  BURKE, Stephen, James ,  LIU, Liqin ,  MOORE, Paul, A. ,  BONVINI, Ezio ,  BARAT, Bhaswati

IPC分类号： C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61P1/04 ,  A61P1/16 ,  A61P5/00 ,  A61P9/10 ,  A61P11/00 ,  A61P13/10 ,  A61P13/12 ,  A61P17/00 ,  A61P19/00 ,  A61P21/00 ,  A61P35/02 ,  A61P35/00 ,  A61P35/04 ,  A61P1/18 ,  A61P13/00 ,  A61P13/08 ,  A61P15/00 ,  A61P25/00

摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

公开(公告)号：EP3197917A1

公开(公告)日：2017-08-02

申请号：EP15844698.9

申请日：2015-09-22

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie, S. ,  BONVINI, Ezio ,  LAM, Chia-ying, Kao ,  MOORE, Paul, A. ,  LIU, Liqin ,  KOENIG, Scott

IPC分类号： C07K16/28

CPC分类号： C07K16/2803 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/2896 ,  C07K16/3061 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

摘要： CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.

摘要翻译： CD 19xCD3双特异性单价双抗体，特别是CD19xCD3双特异性单价Fc双抗体能够同时结合CD19和CD3，并用于治疗血液恶性肿瘤。

公开(公告)号：EP3724231A1

公开(公告)日：2020-10-21

申请号：EP18889206.1

申请日：2018-12-06

申请人： MacroGenics, Inc.

发明人： DIEDRICH, Gundo ,  LIU, Liqin ,  LI, Hua Watson ,  JOHNSON, Leslie, S.

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61K39/385

公开(公告)号：EP3585431A1

公开(公告)日：2020-01-01

申请号：EP18757875.2

申请日：2018-02-22

申请人： MacroGenics, Inc.

发明人： LIU, Liqin ,  LAM, Chia-ying, Kao ,  DIEDRICH, Gundo ,  JOHNSON, Leslie, S. ,  MOORE, Paul, A. ,  BONVINI, Ezio

IPC分类号： A61K39/395 ,  A61P35/00

公开(公告)号：EP3954703A2

公开(公告)日：2022-02-16

申请号：EP21185550.7

申请日：2015-05-29

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie S. ,  HUANG, Ling ,  CHICHILI, Gurunadh Reddy ,  SHAH, Kalpana ,  LAM, Chia-Ying, Kao ,  BURKE, Stephen, James ,  LIU, Liqin ,  MOORE, Paul, A. ,  BONVINI, Ezio ,  BARAT, Bhaswati

IPC分类号： C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61P1/04 ,  A61P1/16 ,  A61P5/00 ,  A61P9/10 ,  A61P11/00 ,  A61P13/10 ,  A61P13/12 ,  A61P17/00 ,  A61P19/00 ,  A61P21/00 ,  A61P35/02 ,  A61P35/00 ,  A61P35/04 ,  A61P1/18 ,  A61P13/00 ,  A61P13/08 ,  A61P15/00 ,  A61P25/00

摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

公开(公告)号：EP3839044A1

公开(公告)日：2021-06-23

申请号：EP20217972.7

申请日：2014-03-13

申请人： MacroGenics, Inc. ,  Duke University

发明人： KOENIG, Scott ,  JOHNSON, Leslie S. ,  LAM, Chia-Ying Kao ,  LIU, Liqin ,  NORDSTROM, Jeffrey Lee ,  HAYNES, Barton F. ,  FERRARI, Guido

IPC分类号： C12N5/16 ,  A61K39/12 ,  A61K45/00 ,  A61K39/00 ,  A61K39/38 ,  A01N65/00 ,  C12N7/00 ,  C12N7/01 ,  C12N5/07 ,  C07K16/10

摘要： The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.

公开(公告)号：EP3794027A1

公开(公告)日：2021-03-24

申请号：EP19802868.0

申请日：2019-05-13

申请人： MacroGenics, Inc. ,  Duke University

发明人： LAM, Chia-Ying, Kao ,  DIEDRICH, Gundo ,  NORDSTROM, Jeffrey, Lee ,  LIU, Liqin ,  JOHNSON, Leslie, S. ,  KOENIG, Scott ,  HAYNES, Barton, F. ,  FERRARI, Guido

IPC分类号： C07K16/10 ,  C07K16/28